| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
FFN200 targets the vesicular monoamine transporter 2 (VMAT2), a protein responsible for packaging monoamine neurotransmitters (dopamine, norepinephrine, serotonin, histamine) into synaptic vesicles. It acts as a substrate for VMAT2, allowing selective tracing of monoamine exocytosis. FFN200 is a fluorescent substrate that enables visualization of vesicular monoamine dynamics.
|
|---|---|
| ln Vitro |
Dopaminergic neurons absorb FFN200 dihydrochloride without the aid of DAT or other Na+-dependent transporters [1].
In vitro, FFN200 acts as a fluorescent substrate of VMAT2 that selectively traces monoamine exocytosis in neuronal cell culture. The compound's fluorescence allows real-time visualization of vesicular monoamine release and recycling. The fluorescence excitation and emission maxima are 352 nm and 451 nm, respectively. FFN200 enables tracking of monoamine exocytosis with high spatial and temporal resolution. |
| ln Vivo |
In vivo, FFN200 selectively traces monoamine exocytosis in brain tissue. It allows researchers to visualize and study monoamine neurotransmitter dynamics in living animals. The compound is used as a research tool to investigate the mechanisms of vesicular monoamine transport and release in the brain. Specific in vivo activity data are not extensively documented.
|
| Enzyme Assay |
The in vitro assay for FFN200 involves treating cultured neuronal cells with the compound and visualizing its fluorescence using confocal microscopy. FFN200 is taken up by VMAT2 into synaptic vesicles, and its fluorescence (excitation 352 nm, emission 451 nm) allows tracking of vesicular monoamine dynamics. The compound's ability to selectively trace monoamine exocytosis is assessed by measuring changes in fluorescence intensity upon stimulation of neurotransmitter release.
|
| Cell Assay |
In vitro cellular assays for FFN200 involve culturing primary neurons or neuronal cell lines and treating them with FFN200 at appropriate concentrations. Cells are imaged using fluorescence microscopy or confocal microscopy to visualize VMAT2-mediated uptake and vesicular trafficking. Stimulation of neurotransmitter release (e.g., using high potassium or electrical stimulation) induces fluorescence changes that are quantified to assess exocytosis.
|
| Animal Protocol |
In vivo animal experiments for FFN200 involve administering the compound to rodents via intracerebral injection or systemic routes. Brain tissue is examined using fluorescence imaging techniques to visualize VMAT2-expressing neurons and monoamine exocytosis. FFN200 allows researchers to study vesicular monoamine dynamics in living brain tissue. Specific protocols are not extensively documented but are established in the neuroscience literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of FFN200 have not been extensively characterized in publicly available literature. The compound is administered as a research tool for imaging studies. FFN200 has a molecular weight of 277.15 (C11H14Cl2N2O2). Its ability to reach brain tissue and be taken up by VMAT2-expressing neurons is a key feature for its use as a fluorescent tracer.
|
| Toxicity/Toxicokinetics |
Toxicological (toxicology) data for FFN200 are limited in publicly available sources. As a research tool used in cellular and brain tissue imaging studies, FFN200 is typically used at low concentrations that are not expected to cause significant toxicity. However, systematic toxicology studies have not been well documented. Standard safety assessments would be required for any therapeutic development.
|
| References | |
| Additional Infomation |
FFN200 HCl (CAS#: 2080306-27-8) is a novel fluorescent substrate of vesicular monoamine transporter 2 (VMAT2). It selectively traces monoamine exocytosis in neuronal cell culture and brain tissue. The compound has fluorescence excitation and emission maxima of 352 nm and 451 nm, respectively. FFN200 is not approved for clinical use and remains a research tool for studying vesicular monoamine dynamics and neurotransmission.
|
| Molecular Formula |
C11H14CL2N2O2
|
|---|---|
| Molecular Weight |
277.147060871124
|
| Exact Mass |
276.043
|
| CAS # |
2080306-27-8
|
| Related CAS # |
2080306-26-7;2080306-27-8 (2HCl);
|
| PubChem CID |
124201850
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
288
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.Cl.O1C(C=C(CCN)C2C=CC(=CC1=2)N)=O
|
| InChi Key |
YNQXRSNAOWBGLD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H12N2O2.2ClH/c12-4-3-7-5-11(14)15-10-6-8(13)1-2-9(7)10/h1-2,5-6H,3-4,12-13H22*1H
|
| Chemical Name |
4-(2-Aminoethyl)-7-amino-2H-1-benzopyran-2-one dihydrochloride
|
| Synonyms |
FFN200 dihydrochloride FFN-200 FFN200 FFN200 HClFFN 200.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6082 mL | 18.0408 mL | 36.0815 mL | |
| 5 mM | 0.7216 mL | 3.6082 mL | 7.2163 mL | |
| 10 mM | 0.3608 mL | 1.8041 mL | 3.6082 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA